Chandler Robinson Monopar Therapeutics (MNPR) insider trading activity

Chandler Robinson is Chief Executive Officer of Monopar Therapeutics. Currently has a direct ownership of 56,162 shares of MNPR, which is worth approximately $1.4 Million. The most recent transaction as insider was on Sep 30, 2024, when has been sold 1,918 shares (Common Stock) at a price of $6.74 per share, resulting in proceeds of $12,927. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 56.2K

78.88% 3M change

56.27% 12M change

Total Value Held $1.4 Million

Chandler Robinson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 30 2024	SELL Payment of exercise price or tax liability	$12,927 $6.74 p/Share	1,918 Reduced 3.3%	56,162 Common Stock
Sep 30 2024	BUY Exercise of conversion of derivative security	-	4,895 Added 7.77%	58,080 Common Stock
Jun 30 2024	SELL Payment of exercise price or tax liability	$6,339 $0.73 p/Share	8,684 Reduced 3.16%	265,922 Common Stock
Jun 30 2024	BUY Exercise of conversion of derivative security	-	24,476 Added 8.18%	274,606 Common Stock
May 28 2024	BUY Exercise of in-the-money or at-the-money derivatives securities	-	84,000 Added 25.14%	250,130 Common Stock
Mar 31 2024	SELL Payment of exercise price or tax liability	$4,876 $0.68 p/Share	7,172 Reduced 4.14%	166,130 Common Stock
Mar 31 2024	BUY Exercise of conversion of derivative security	-	24,474 Added 12.37%	173,302 Common Stock
Jan 01 2024	SELL Payment of exercise price or tax liability	$791 $0.34 p/Share	2,327 Reduced 1.54%	148,828 Common Stock
Jan 01 2024	BUY Exercise of conversion of derivative security	-	6,724 Added 4.26%	151,155 Common Stock
Dec 31 2023	SELL Payment of exercise price or tax liability	$2,879 $0.34 p/Share	8,469 Reduced 5.54%	144,431 Common Stock
Dec 31 2023	BUY Exercise of conversion of derivative security	-	24,474 Added 13.8%	152,900 Common Stock
Sep 30 2023	SELL Payment of exercise price or tax liability	$4,446 $0.62 p/Share	7,172 Reduced 5.29%	128,426 Common Stock
Sep 30 2023	BUY Exercise of conversion of derivative security	-	24,474 Added 15.29%	135,598 Common Stock
Jun 30 2023	SELL Payment of exercise price or tax liability	$8,831 $0.86 p/Share	10,269 Reduced 8.46%	111,124 Common Stock
Jun 30 2023	BUY Exercise of conversion of derivative security	-	35,039 Added 22.4%	121,393 Common Stock
Mar 31 2023	SELL Payment of exercise price or tax liability	$5,957 $1.39 p/Share	4,286 Reduced 4.73%	86,354 Common Stock
Mar 31 2023	BUY Exercise of conversion of derivative security	-	13,911 Added 13.31%	90,640 Common Stock
Jan 01 2023	SELL Payment of exercise price or tax liability	$5,514 $2.37 p/Share	2,327 Reduced 2.94%	76,729 Common Stock
Jan 01 2023	BUY Exercise of conversion of derivative security	-	6,723 Added 7.84%	79,056 Common Stock
Dec 31 2022	SELL Payment of exercise price or tax liability	$11,409 $2.37 p/Share	4,814 Reduced 6.24%	72,333 Common Stock
Dec 31 2022	BUY Exercise of conversion of derivative security	-	13,912 Added 15.28%	77,147 Common Stock
Sep 30 2022	SELL Payment of exercise price or tax liability	$6,197 $1.52 p/Share	4,077 Reduced 6.06%	63,235 Common Stock
Sep 30 2022	BUY Exercise of conversion of derivative security	-	13,911 Added 17.13%	67,312 Common Stock
Jun 30 2022	SELL Payment of exercise price or tax liability	$16,098 $2.3 p/Share	6,999 Reduced 11.59%	53,401 Common Stock
Jun 30 2022	BUY Exercise of conversion of derivative security	-	23,882 Added 28.34%	60,400 Common Stock

Chandler Robinson

Chief Executive Officer

Wilmette, IL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MNPR shares.

Notify only if

Value

Insider Trading

Get notified when an Monopar Therapeutics insider buys or sells MNPR shares.

Notify only if

Operation

Value

Type

News

Receive news related to Monopar Therapeutics

Track Activities on MNPR

Account